Xenon Pharmaceuticals Inc. - Common Shares (XENE)
CUSIP: 98420N105
Q4 2016 13F Holders as of 31 Dec 2016
- Type / Class
- Equity / Common Shares
- Shares outstanding
- 92,799,600
- Total 13F shares
- 10,492,956
- Share change
- +245,251
- Total reported value
- $80,798,000
- Price per share
- $7.70
- Number of holders
- 31
- Value change
- +$1,871,735
- Number of buys
- 10
- Number of sells
- 15
Quarterly Holders Quick Answers
What is CUSIP 98420N105?
CUSIP 98420N105 identifies XENE - Xenon Pharmaceuticals Inc. - Common Shares in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 98420N105:
Top shareholders of XENE - Xenon Pharmaceuticals Inc. - Common Shares (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BVF INC/IL |
13F
|
Company |
3.4%
|
3,108,905
|
$25,182,000 | — | 30 Sep 2016 | |
| Capital World Investors |
13F
|
Company |
1.1%
|
1,030,000
|
$8,343,000 | — | 30 Sep 2016 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
1.1%
|
1,000,000
|
$8,100,000 | — | 30 Sep 2016 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
0.82%
|
762,800
|
$6,179,000 | — | 30 Sep 2016 | |
| Tekla Capital Management LLC |
13F
|
Company |
0.75%
|
700,000
|
$5,670,000 | — | 30 Sep 2016 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.55%
|
514,091
|
$4,164,000 | — | 30 Sep 2016 | |
| Invesco Private Capital, Inc. |
13F
|
Company |
0.44%
|
412,479
|
$3,341,000 | — | 30 Sep 2016 | |
| Opaleye Management Inc. |
13F
|
Company |
0.44%
|
410,000
|
$3,321,000 | — | 30 Sep 2016 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.4%
|
367,311
|
$2,975,000 | — | 30 Sep 2016 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.39%
|
358,531
|
$2,904,000 | — | 30 Sep 2016 | |
| Ghost Tree Capital, LLC |
13F
|
Company |
0.35%
|
325,000
|
$2,633,000 | — | 30 Sep 2016 | |
| HIGHLAND CAPITAL MANAGEMENT LP |
13F
|
Company |
0.27%
|
250,000
|
$2,025,000 | — | 30 Sep 2016 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
0.25%
|
228,029
|
$1,847,000 | — | 30 Sep 2016 | |
| Novo Holdings A/S |
13F
|
Company |
0.14%
|
127,563
|
$1,033,000 | — | 30 Sep 2016 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.1%
|
96,200
|
$779,000 | — | 30 Sep 2016 | |
| State of New Jersey Common Pension Fund D |
13F
|
Company |
0.07%
|
65,000
|
$527,000 | — | 30 Sep 2016 | |
| Weiss Multi-Strategy Advisers LLC |
13F
|
Company |
0.03%
|
31,500
|
$255,000 | — | 30 Sep 2016 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.03%
|
28,748
|
$232,000 | — | 30 Sep 2016 | |
| Leith Wheeler Investment Counsel Ltd. |
13F
|
Company |
0.02%
|
16,075
|
$171,000 | — | 30 Sep 2016 | |
| SCOTIA CAPITAL INC. |
13F
|
Company |
0.02%
|
20,820
|
$169,000 | — | 30 Sep 2016 | |
| NJ State Employees Deferred Compensation Plan |
13F
|
Company |
0.02%
|
20,000
|
$162,000 | — | 30 Sep 2016 | |
| K2 PRINCIPAL FUND, L.P. |
13F
|
Company |
0.02%
|
15,000
|
$122,000 | — | 30 Sep 2016 | |
| M&T BANK CORP |
13F
|
Company |
0.02%
|
14,251
|
$115,000 | — | 30 Sep 2016 | |
| BANK OF MONTREAL /CAN/ |
13F
|
Company |
0.01%
|
7,137
|
$58,000 | — | 30 Sep 2016 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
2,811
|
$23,000 | — | 30 Sep 2016 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
2,464
|
$20,000 | — | 30 Sep 2016 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
1,700
|
$14,000 | — | 30 Sep 2016 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
987
|
$8,000 | — | 30 Sep 2016 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
700
|
$6,000 | — | 30 Sep 2016 | |
| UBS Group AG |
13F
|
Company |
0%
|
617
|
$5,000 | — | 30 Sep 2016 |
Institutional Holders of Xenon Pharmaceuticals Inc. - Common Shares (XENE) as of Q4 2016
As of 31 Dec 2016,
Xenon Pharmaceuticals Inc. - Common Shares (XENE) was held by
31 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
10,492,956 shares.
The largest 10 holders included
BVF INC/IL, Capital World Investors, ORBIMED ADVISORS LLC, PERCEPTIVE ADVISORS LLC, Tekla Capital Management LLC, DAFNA Capital Management LLC, Opaleye Management Inc., Invesco Private Capital, Inc., SPHERA FUNDS MANAGEMENT LTD., and Ghost Tree Capital, LLC.
This page lists
31
institutional shareholders reporting positions in this security
for the Q4 2016 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2016 vs Q3 2016 Across Filers
Q3 2016 holders
31
Q4 2016 holders
31
Holder diff
0
| Investor | Q3 2016 Shares | Q4 2016 Shares | Share Diff | Share Chg % | Q3 2016 Value $ | Q4 2016 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.